|
With essentially no direct competition in this treatment category, the addressable market is huge and the impact of an approval for pancreatic cancer sufferers and PharmaCyte shareholders would be enormous. ...
If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment ...
PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
Investment ...
Recent and pending events infer that the road to approval and marketing of Pharmacyte's flagship pancreatic cancer treatment has been dramatically shortened, potentially leading to a banner year 2016 for ...
PMCB's approach to diabetes therapy could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them.
.report-main ...
Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment ...
PharmaCyte Biotech’s Cell Encapsulation Approach to Treat Diabetes Could Prove Superior to Other Encapsulation Techniques
Following decades of failed research, a great deal of attention ...
PharmaCyte Biotech (OTC – PMCB) may be undervalued today but that is not likely to last. See why it could quickly return to its highs of six months ago.
.report-main h1{
color:#014e92;
font-size:30px;
}
.report-main ...
One of the untold stories behind PharmaCyte Biotech’s (OTCQB – PMCB - $0.159) success is that the formation and implementation of its International Diabetes Consortium has already resulted in ...
A major scientific journal recently published a study led by one of PMCB’s Diabetes Consortium members. The animal study showed that a new cell line designed by the study’s authors have ...
Since the Company’s Cell-in-a-Box(R) live cell encapsulation technology has such broad potential applications, it could emerge as a universal therapy for the treatment of multiple forms of ...
In an era when small biotech companies may only launch one trial a year, having three, high profile, abdominal cancer trial events to look forward to this year could put PharmaCyte Biotech on the map. ...
It has been over a year since we have written about PharmaCyte Biotech (OTCQB – PMCB), formerly Nuvilex we believe that these shares are grossly undervalued in light of the Company’s increasingly ...
|
||
|
|
||